Thera-SAbDab

CUSATUZUMAB

>   Structural Summary
TherapeuticCusatuzumab
TargetCD70
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS
Light ChainQAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology;SIMPLE Antibody Technology
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedarGEN-X
Conditions Approvedna
Conditions ActiveCutaneous T-cell lymphoma, Acute myeloid leukaemia, Haematological malignancies, Myelodysplastic syndromes, Solid tumours, Autoimmune disorders
Conditions DiscontinuedNasopharyngeal cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]